Full Press Release Details
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell, an Immunotherapeutic for Chronic Hepatitis B.
ALT
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell, an Immunotherapeutic for Chronic Hepatitis B
Key Takeaway: Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell, an Immunotherapeutic for Chronic Hepatitis B
Price reaction · baseline $4.04 (2023-04-10 close) · hit after-hours · clean, no other ALT news in the window
day 0 close · peak
+2.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight